APO-RIVASTIGMINE 6 MG
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 6 MG · DIN 02336758 · APOTEX INC
Health Canada status: MARKETED
What is APO-RIVASTIGMINE?
APO-RIVASTIGMINE 6 MG contains RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 6 MG. It is listed in the Health Canada Drug Product Database under DIN 02336758, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Apr-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-RIVASTIGMINE used for?
Symptomatic treatment of mild to moderate dementia of the Alzheimer's type or mild to moderate dementia associated with idiopathic Parkinson’s disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02336758 |
|---|---|
| Brand name | APO-RIVASTIGMINE |
| Generic / active ingredient | RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 6 MG |
| Manufacturer | APOTEX INC |
| Strength | 6 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06DA03 RIVASTIGMINE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Apr-2010 |
| Original market date | 2010-04-07 00:00:00 |
How is it administered?
Take with food in divided doses (morning/evening). Start at 1.5 mg b.i.d. Titrate based on tolerability every 2-4 weeks. Usual maintenance: 6-12 mg/day. Re-titrate if interrupted >3 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard section 11 was listed in TOC but text cut off).
How is it supplied?
Bottles of 100 and blister packages of 10 capsules.
Contraindications
Hypersensitivity to rivastigmine or carbamates; severe liver impairment; history of application site reactions to patches; history of QT prolongation, torsade de pointes, or cardiac arrhythmias.
Warnings and precautions
Gastrointestinal effects (severe nausea/vomiting); vagotonic effects on heart rate (bradycardia, syncopal episodes); QTc prolongation; weight loss; risk of pancreatitis; skin reactions.
What can be used instead?
Other Canadian products sharing ATC code N06DA03 RIVASTIGMINE. 28 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 1.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336715 |
| APO-RIVASTIGMINE | 3 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336723 |
| APO-RIVASTIGMINE | 4.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02336731 |
| EXELON | 1.5 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242115 |
| EXELON | 2 MG | SOLUTION | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02245240 |
| EXELON | 3 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242116 |
| EXELON | 4.5 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242117 |
| EXELON | 6 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02242118 |
| EXELON PATCH 10 | 9.5 MG / 24 HOUR | PATCH | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02302853 |
| EXELON PATCH 15 | 13.3 MG / 24 HOUR | PATCH | KNIGHT THERAPEUTICS INC. | MARKETED | DIN 02432803 |
Who else supplies RIVASTIGMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIVASTIGMINE appears in 242 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.